Drug Profile
Uroguanylin
Latest Information Update: 13 Jan 2003
Price :
$50
*
At a glance
- Originator Unknown
- Developer Nonindustrial source; Pharmacia Corporation
- Class Antineoplastics; Peptide hormones
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 13 Jan 2003 No development reported - Preclinical for Colorectal cancer in USA (unspecified route)
- 14 Nov 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation
- 08 Nov 2000 Preclinical development for Colorectal cancer in USA (Unknown route)